Sodium‐glucose co‐transporter‐2 inhibitors as add‐on therapy to insulin for type 1 diabetes mellitus: Systematic review and meta‐analysis of randomized controlled trials
Author:
Affiliation:
1. Department of Diabetes and Metabolic Diseases, Graduate School of Medicine University of Tokyo Tokyo Japan
2. Department of Data Science The Institute of Statistical Mathematics Tokyo Japan
Funder
Japan Society for the Promotion of Science
Japan Foundation for Applied Enzymology
Publisher
Wiley
Subject
Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine
Link
https://onlinelibrary.wiley.com/doi/pdf/10.1111/dom.13260
Reference31 articles.
1. Type 1 Diabetes Through the Life Span: A Position Statement of the American Diabetes Association
2. Current State of Type 1 Diabetes Treatment in the U.S.: Updated Data From the T1D Exchange Clinic Registry
3. Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis
4. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
5. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Cited by 70 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Glucagon secretion and its association with glycaemic control and ketogenesis during sodium‐glucose cotransporter 2 inhibition by ipragliflozin in people with type 1 diabetes: Results from the multicentre, open‐label, prospective study;Diabetes, Obesity and Metabolism;2024-01-22
2. The effect of sodium-glucose cotransporter 2 inhibitors as an adjunct to insulin in patients with type 1 diabetes assessed by continuous glucose monitoring: A systematic review and meta-analysis;Journal of Diabetes and its Complications;2023-12
3. Sodium glucose cotransporter2 inhibitors for type 1 diabetes mellitus: A meta-analysis of randomized controlled trials;Primary Care Diabetes;2023-11
4. 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes;European Heart Journal;2023-08-25
5. SGLT2i in Patients with Type 1 Diabetes: Benefits, Risks, and Preventive Strategies;Frontiers in Bioscience-Landmark;2023-05-22
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3